2022 American Transplant Congress
Clinical Features and Outcomes of Hospitalized Solid Organ Transplant and Hematopoietic Stem Cell Recipients with Sars-CoV-2 Infection in the Midwestern United States: A Multi-Center Retrospective Cohort Study
*Purpose: Immunocompromised hosts are at risk for severe complications or death from SARS-CoV-2 infection. Few studies describe the clinical features, outcomes and treatment strategies in…2022 American Transplant Congress
Letermovir for Prophylaxis of Cytomegalovirus After Solid Organ Transplantation: A Single-Center, Observational Study
*Purpose: Cytomegalovirus (CMV) infections cause significant complications post-transplant; however, prophylactic medications are often limited by toxicities. Letermovir is a novel terminase inhibitor specific to CMV…2022 American Transplant Congress
Post-Kidney Transplant Valacyclovir versus Valganciclovir for CMV Prophylaxis: A Randomized Controlled Trial
*Purpose: Valganciclovir (valG) is an effective CMV prophylactic agent post-kidney transplant (KTx) with significant side effects. Valacyclovir (valA) may be effective for CMV prophylaxis with…2022 American Transplant Congress
Use of Viral Specific T Cell Therapy in Solid Organ Transplant Recipients – A Single Center Experience
*Purpose: Viral infections such as BK virus (BKV), cytomegalovirus (CMV) and adenovirus after kidney transplantation negatively impact outcomes in solid organ transplant (SOT) recipients despite…2022 American Transplant Congress
Impact of Glecaprevir/Pibrentasvir on Tacrolimus Concentration in Solid Organ Transplant Recipients with or without Triazole Antifungal Therapy
*Purpose: Provide guidance on tacrolimus (TAC) dose adjustments during glecaprevir/pibrentasvir (GLE/PIB) initiation and discontinuation in patients on triazole antifungals by comparing changes in TAC concentration-dose…2022 American Transplant Congress
The Prevalence And Risk Factors Of De Novo Hepatitis B Virus Infection In Kidney Transplantation From Hepatitis B Antigen-positive Donors To Hbsag-negative Recipients
1urology, west china hospital, Chengdu, China, 2Urology, West China Hospital, Chengdu, China
*Purpose: To explore the prevalence and risk factors of de novo HBV infection (DNH) in kidney transplantation (KT) from HBsAg⁺ donors (D[HBsAg⁺]) to HBsAg-negative recipients…2022 American Transplant Congress
Evaluation of the Management of Cytomegalovirus in Kidney Transplant Recipients After Establishment of a Multidisciplinary Cytomegalovirus Workgroup
Hennepin County Medical Center, Minneapolis, MN
*Purpose: To assess the effectiveness of a multidisciplinary cytomegalovirus (CMV) workgroup in managing CMV in kidney transplant recipients.*Methods: Retrospective chart review at a single transplant…2022 American Transplant Congress
Ultra-Short Duration Prophylaxis for Hepatitis C Donor Positive to Recipient Negative Simultaneous Kidney/Pancreas Transplants
Virginia Commonwealth University, Richmond, VA
*Purpose: Recent trials have successfully utilized a strategy of hepatitis C virus (HCV) D+ [Donor nucleic acid test (NAT) positive]/R- (Recipient NAT negative) kidney and/or…2022 American Transplant Congress
Preemptive Therapy for Cytomegalovirus (CMV) Disease Prevention in High-Risk CMV Donor Seropositive Recipient Seronegative (D+/R-) Liver Transplant Recipients in a Real-World Setting
*Purpose: Preemptive therapy (PET) has demonstrated superiority to antiviral prophylaxis for prevention of cytomegalovirus (CMV) disease in CMV donor seropositive/recipient seronegative (D+R-) liver transplant recipients …2022 American Transplant Congress
Use of Targeted T-Cell Therapy (Posoleucel) for the Treatment of Epstein-Barr Virus Associated Leiomyosarcoma in an Adult Kidney Transplant Recipient: A Case Report
*Purpose: Epstein-Barr virus (EBV)-associated leiomyosarcomas (EBV+LMS) are neoplasms rarely seen in solid organ transplant (SOT) recipients and currently lack effective treatment options. We present a…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 14
- Next Page »